olaparib
Showing 1 - 25 of 230
Metastatic Breast Cancer Trial (Olaparib, 17b-estradiol)
Not yet recruiting
- Metastatic Breast Cancer
- Olaparib
- 17b-estradiol
- (no location specified)
Jun 2, 2023
Carcinoma, Ovarian Epithelial Trial in San Fermo Della Battaglia, Padova (Olaparib, Bevacizumab)
Recruiting
- Carcinoma, Ovarian Epithelial
- Olaparib
- Bevacizumab
-
San Fermo Della Battaglia, Como, Italy
- +1 more
Nov 2, 2023
Gastric Cancer, GastroEsophageal Cancer Trial in Aurora, Colorado Springs, Highlands Ranch (Pembrolizumab, Olaparib,
Recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- Pembrolizumab
- +2 more
-
Aurora, Colorado
- +2 more
Jan 4, 2023
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)
Not yet recruiting
- Ovary Cancer
- +2 more
- Mirvetuximab Soravtansine
- Olaparib
-
Aurora, ColoradoUniversity of Colorado Hospital
May 30, 2023
Pancreatic Acinar Cell Carcinoma Trial run by the National Cancer Institute (NCI) (Olaparib)
Recruiting
- Pancreatic Acinar Cell Carcinoma
- Olaparib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Prostate Cancer Aggressiveness, Prostate Carcinoma Trial in Houston (Cabazitaxel, Carboplatin, Prednisone 5Mg)
Active, not recruiting
- Prostate Cancer Aggressiveness
- Prostate Carcinoma
- Cabazitaxel
- +3 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 5, 2022
Sarcoma, Sarcoma Metastatic Trial in Ann Arbor (Olaparib, Trabectedin)
Active, not recruiting
- Sarcoma
- Sarcoma Metastatic
- Olaparib
- Trabectedin
-
Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
Dec 20, 2022
Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer Trial (AsiDNA, Olaparib)
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- +2 more
- AsiDNA
- Olaparib
- (no location specified)
Jan 17, 2023
Metastatic Breast Cancer Trial in Taipei City, Taipei, Yuanlin (Olaparib, Chemotherapy drug)
Recruiting
- Metastatic Breast Cancer
- Olaparib
- Chemotherapy drug
-
Taipei City, Please Select, Taiwan
- +2 more
Nov 27, 2022
Breast Cancer Trial in Los Angeles (Pembrolizumab, Olaparib)
Active, not recruiting
- Breast Cancer
- Pembrolizumab
- Olaparib
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
Feb 1, 2023
Urothelial Carcinoma, Urothelial Cancer, Lung Tumors Trial run by the NCI (EP0057, olaparib)
Recruiting
- Urothelial Carcinoma
- +4 more
- EP0057
- olaparib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Prostate Cancer Trial in Lexington (biological, drug, radiation)
Not yet recruiting
- Prostate Cancer
- Pembrolizumab
- +3 more
-
Lexington, KentuckyUniversity of Kentucky
Oct 3, 2022
Advanced Solid Tumor, Metastatic Solid Tumor Trial (ART6043, Olaparib, Talazoparib)
Not yet recruiting
- Advanced Solid Tumor
- Metastatic Solid Tumor
- ART6043
- +2 more
- (no location specified)
Jun 1, 2023
Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)
Not yet recruiting
- Advanced Solid Tumor
- Non-small Cell Lung Cancers
- Adagrasib
- Olaparib
-
Houston, TexasM D Anderson Cancer Center
Nov 15, 2023
Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Tumors Trial run by the National Cancer Institute (NCI)
Recruiting
- Gastroenteropancreatico Tumors
- +2 more
- Lu-177-DOTATATE
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 19, 2023
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a
Recruiting
- ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
- a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
- Durvalumab
- +2 more
-
Montpellier, France
- +1 more
Nov 16, 2022
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Olaparib)
Recruiting
- Castration-Resistant Prostate Carcinoma
- Prostate Adenocarcinoma
- Olaparib
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 23, 2022
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)
Recruiting
- EGFR-Mutated Non-Small-Cell Lung Carcinoma
- Small Cell/Neuroendocrine
- Olaparib
- Durvalumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Breast Cancer Trial in Spain (Olaparib)
Terminated
- Breast Cancer
- Olaparib
-
Barcelona, Spain
- +7 more
Jan 18, 2023
Recurrent Metastatic Melanoma, Cutaneous Melanoma, Mucosal Melanoma Trial in Boston (Olaparib)
Not yet recruiting
- Recurrent Metastatic Melanoma
- +3 more
- Olaparib
-
Boston, Massachusetts
- +1 more
Jul 29, 2022
Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8 Trial in New York
Recruiting
- Locally Advanced Leiomyosarcoma
- +5 more
- Olaparib
- +3 more
-
New York, New YorkColumbia University/Herbert Irving Cancer Center
Jan 4, 2023
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Adavosertib
- +2 more
-
Boston, Massachusetts
- +1 more
Jan 12, 2023
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)
Recruiting
- Biochemically Recurrent Prostate Carcinoma
- Prostate Adenocarcinoma
- Durvalumab
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 26, 2023
Laryngeal Cancer Stage II, Laryngeal Cancer Stage III, Carcinoma, Squamous Cell Trial in Amsterdam (radiotherapy, Olaparib)
Active, not recruiting
- Laryngeal Cancer Stage II
- +3 more
- radiotherapy
- Olaparib
-
Amsterdam, NetherlandsThe Netherlands Cancer Institute
Sep 27, 2022